Following the breakthrough deal with GlaxoSmithKline, Spero is in a comfortable position to advance its pipeline. The $150 million non-performance related milestone payment, equivalent to $3.2 per ...

Earnings Estimate Revisions for Spero Therapeutics This company is expected to earn -$1.20 per share for the fiscal year ending December 2024, which represents a year-over-year change of -379.1%.

Shai Biran; Investor Relations; Spero Therapeutics Inc. Esther Rajavelu; Interim President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Chief Business Officer; Spero ...

Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to strip away its remaining pipeline. The latest program to be discontinued is SPR206, a next-gen polymyxin ...

Spero is eligible to receive up to $525 million in development and sales milestone payments as well as royalties on net product sales under the agreement with GSK. In addition, Spero has two other ...

Spero Therapeutics (NASDAQ:SPRO) Friday named Esther Rajavelu as Interim President and Chief Executive Officer, stepping in for Sath Shukla, who has agreed to a voluntary paid administrative leave ...

Not much went right for Spero Therapeutics’ SPR720 in its phase 2a trial. An interim analysis revealed a double blow to the oral antibiotic candidate, which both failed to beat placebo and ...

June 27 (Reuters) - The U.S. Food and Drug Administration (FDA) declined to approve Spero Therapeutics Inc's (SPRO.O), opens new tab oral antibiotic drug for the treatment of patients with ...